"AbbVie is a Dividend King with a proven track record. The quarterly dividend has risen every year since the company's 2013 spin-off from Abbott Laboratories, climbing from $0.40 per quarter in 2013 to $1.73 per quarter today."
"AbbVie posted record net sales in just the second full year following the U.S. Humira loss of exclusivity, with full-year 2025 revenue reaching $61.16 billion, up 8.57% year-over-year."
"Skyrizi generated $5 billion in Q4 2025 alone, up 32.5% year-over-year, and Rinvoq added $2.37 billion in Q4, up 29.5%. Rinvoq now carries 9 U.S. approved indications."
"The trailing P/E looks elevated at 88x, but that's distorted by massive acquired In Process Research & Development charges totaling $5 billion pre-tax for full-year 2025."
AbbVie has shown resilience with a 7.03% decline year-to-date, currently priced at $208.99. The company is a Dividend King, increasing its quarterly dividend from $0.40 in 2013 to $1.73 today. Skyrizi and Rinvoq are successfully replacing Humira, with record net sales of $61.16 billion in 2025. Despite Humira's decline, AbbVie's immunology segment grew 18.3%. The company's forward valuation is considered undervalued due to significant R&D charges that distort the trailing P/E ratio.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]